AnaptysBio Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $18.055
- Today's High:
- $18.8
- Open Price:
- $18.55
- 52W Low:
- $18.2
- 52W High:
- $32.435
- Prev. Close:
- $18.48
- Volume:
- 154942
Company Statistics
- Market Cap.:
- $657.50 million
- Book Value:
- 9.192
- Revenue TTM:
- $10.29 million
- Operating Margin TTM:
- -1119.41%
- Gross Profit TTM:
- $-78511000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -11.48%
- Return on Equity TTM:
- -41.62%
Company Profile
AnaptysBio Inc had its IPO on 2017-01-26 under the ticker symbol ANAB.
The company operates in the Healthcare sector and Biotechnology industry. AnaptysBio Inc has a staff strength of 96 employees.
Stock update
Shares of AnaptysBio Inc opened at $18.55 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $18.06 - $18.8, and closed at $18.72.
This is a +1.3% increase from the previous day's closing price.
A total volume of 154,942 shares were traded at the close of the day’s session.
In the last one week, shares of AnaptysBio Inc have slipped by -1.11%.
AnaptysBio Inc's Key Ratios
AnaptysBio Inc has a market cap of $657.50 million, indicating a price to book ratio of 3.0048 and a price to sales ratio of 178.1566.
In the last 12-months AnaptysBio Inc’s revenue was $10.29 million with a gross profit of $-78511000 and an EBITDA of $-114479000. The EBITDA ratio measures AnaptysBio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, AnaptysBio Inc’s operating margin was -1119.41% while its return on assets stood at -11.48% with a return of equity of -41.62%.
In Q4, AnaptysBio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 573.4%.
AnaptysBio Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-4.54 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into AnaptysBio Inc’s profitability.
AnaptysBio Inc stock is trading at a EV to sales ratio of 91.5495 and a EV to EBITDA ratio of -3.5923. Its price to sales ratio in the trailing 12-months stood at 178.1566.
AnaptysBio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $610.38 million
- Total Liabilities
- $26.05 million
- Operating Cash Flow
- $21.50 million
- Capital Expenditure
- $175000
- Dividend Payout Ratio
- 0%
AnaptysBio Inc ended 2023 with $610.38 million in total assets and $0 in total liabilities. Its intangible assets were valued at $610.38 million while shareholder equity stood at $262.10 million.
AnaptysBio Inc ended 2023 with $0 in deferred long-term liabilities, $26.05 million in other current liabilities, 29000.00 in common stock, $-450477000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $71.31 million and cash and short-term investments were $441.24 million. The company’s total short-term debt was $1,637,000 while long-term debt stood at $0.
AnaptysBio Inc’s total current assets stands at $447.21 million while long-term investments were $142.94 million and short-term investments were $369.93 million. Its net receivables were $1.42 million compared to accounts payable of $2.78 million and inventory worth $0.
In 2023, AnaptysBio Inc's operating cash flow was $21.50 million while its capital expenditure stood at $175000.
Comparatively, AnaptysBio Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $18.72
- 52-Week High
- $32.435
- 52-Week Low
- $18.2
- Analyst Target Price
- $31.5
AnaptysBio Inc stock is currently trading at $18.72 per share. It touched a 52-week high of $32.435 and a 52-week low of $32.435. Analysts tracking the stock have a 12-month average target price of $31.5.
Its 50-day moving average was $20.8 and 200-day moving average was $24.87 The short ratio stood at 11.04 indicating a short percent outstanding of 0%.
Around 31.4% of the company’s stock are held by insiders while 12114% are held by institutions.
Frequently Asked Questions About AnaptysBio Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.